COVID-19 Does Not Lead to an Increase in Corticosteroid Prescriptions in IBD Patients: A Nationwide Cohort Study.
Bente Mertz NørgårdFloor Dijkstra ZegersJan NielsenTorben KnudsenJens KjeldsenPublished in: Inflammatory bowel diseases (2023)
An infection with COVID-19 did not result in a higher rate of filled corticosteroid prescriptions. Using corticosteroids as a proxy for disease activity, COVID-19 did not seem to trigger disease activity, which is a reassuring result for patients with IBD.
Keyphrases
- disease activity
- coronavirus disease
- systemic lupus erythematosus
- rheumatoid arthritis
- sars cov
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- respiratory syndrome coronavirus
- peritoneal dialysis
- prognostic factors
- ulcerative colitis
- patient reported